Onkologie. 2017:11(2):72-77 | DOI: 10.36290/xon.2017.015

Osimertinib – a new treatment option for patients with EGFR mutation T790M

Martin Svatoň, Kristýna Hrdá, Miloš Pešek
Klinika pneumologie a ftizeologie, FN a LF UK Plzeň

Osimertinib belongs to the third generation of tyrosine kinase inhibitors (TKIs) that target the epidermoid growth factor receptor

(EGFR). Good tolerance of osimertinib was demonstrated by the studies of phase I and II. Recently published phase III study (AURA3)

compared effectiveness of osimertinib against platinum doublet in patients with documented T790M mutation after previous

treatment with 1st or 2nd generation EGFR-TKIs. The result was as significantly as clinically improvement in time to progression

(PFS), objective response rate (ORR) and better safety profile and quality of life of patients. Osimertinib therefore become the

new standard for this group of patients with non small cell lung cancer (NSCLC).

Keywords: osimertinib, EGFR, T790M, AURA3

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svatoň M, Hrdá K, Pešek M. Osimertinib – a new treatment option for patients with EGFR mutation T790M. Onkologie. 2017;11(2):72-77. doi: 10.36290/xon.2017.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Meador CB, Jin H, de Stanchina E, et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Mol Cancer Ther 2015; 14(2): 542-552. Go to original source... Go to PubMed...
    2. Soejima K, Yasuda H, Hirano T. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. Expert Rev Clin Pharmacol 2017; 10(1): 31-38. Go to original source... Go to PubMed...
    3. Socinski MA, Villaruz LC, Ross J. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Oncologist 2016; pii: theoncologist. 2016-0285 (epub).
    4. Meador CB, Jin H, de Stanchina E, et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Mol Cancer Ther 2015; 14(2): 542-552. Go to original source... Go to PubMed...
    5. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2016 (epub). Go to original source... Go to PubMed...
    6. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4(9): 1046-1061. Go to original source... Go to PubMed...
    7. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372(18): 1689-1699. Go to original source... Go to PubMed...
    8. Van Der Steen N, Caparello C, Rolfo C, et al. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Onco Targets Ther 2016; 9: 6065-6074. Go to original source... Go to PubMed...
    9. Yang J, Ramalingam SS, Jänne PA, et al. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11(4 Suppl): S152-153. Go to original source...
    10. Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016; 17(12): 1643-1652. Go to original source... Go to PubMed...
    11. Sequist LV, Piotrowska Z, Niederst MJ, et al. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. JAMA Oncol 2016; 2(4): 541-543. Go to original source... Go to PubMed...
    12. Zhang H. Osimertinib making a breakthrough in lung cancer targeted therapy. Onco Targets Ther 2016; 9: 5489-5493. Go to original source... Go to PubMed...
    13. Ramalingam S, Yang JC, Lee CK, et al. LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. J Thorac Oncol 2016; 11(4 Suppl): S152. Go to original source...
    14. Zugazagoitia J, Ferrer I, Paz-Ares L. Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat. Lancet Oncol 2016; 17(12): 1622-1623. Go to original source... Go to PubMed...
    15. Greig SL. Osimertinib: First Global Approval. Drugs. 2016; 76(2): 263-273. Go to original source... Go to PubMed...
    16. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26(21): 3543-3551. Go to original source... Go to PubMed...
    17. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13(3): 247-255. Go to original source... Go to PubMed...
    18. Reichegger H, Jochum W, Förbs D, et al. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. Oncol Res Treat 2016; 39(7-8): 461-463. Go to original source... Go to PubMed...
    19. Oxnard GR, Thress KS, Alden RS, et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34(28): 3375-3382. Go to original source... Go to PubMed...
    20. Mok T, Wu Y, Lee JS, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res 2015; 21(14): 3196-203. Go to original source... Go to PubMed...
    21. Chia PL, Do H, Morey A, et al. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. Lung Cancer 2016; 98: 29-32. Go to original source... Go to PubMed...
    22. Kotake M, Murakami H, Kenmotsu H, et al. High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. Ann Oncol 2016; pii: mdw647 (epub). Go to original source... Go to PubMed...
    23. Mamesaya N, Kenmotsu H, Katsumata M, et al. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. Invest New Drugs 2016 (epub). Go to original source... Go to PubMed...
    24. Ahn MJ, Sun JM, Lee SH, et al. Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision. J Thorac Oncol 2016; 11(12): 2051-2052. Go to original source... Go to PubMed...
    25. Nie KK, Zou X, Geng CX, et al. AZD9291-induced Acute Interstitial Lung Disease. Chin Med J (Engl) 2016; 129(12): 1507-1508. Go to original source... Go to PubMed...
    26. Noonan SA, Sachs PB, Camidge DR. Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment. J Thorac Oncol 2016; 11(12): 2253-2258. Go to original source... Go to PubMed...
    27. Shiroyama T, Hayama M, Satoh S, et al. Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report. Respir Med Case Rep 2016; 20: 25-27. Go to original source...
    28. Ho CC, Liao WY, Lin CA, et al. Brief Report: Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. J Thorac Oncol 2016; pii: S1556-0864(16)33539-0.
    29. Ou SH, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer 2016; 98: 59-61. Go to original source... Go to PubMed...
    30. Planchard D, Loriot Y, André F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 2015; 26(10): 2073-2078. Go to original source... Go to PubMed...
    31. Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin Cancer Res 2016; 22(19): 4837-4847. Go to original source... Go to PubMed...
    32. Wang S, Song Y, Yan F, Liu D. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med 2016 (epub). Go to original source... Go to PubMed...
    33. Li L, Wang H, Li C, et al. Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report. Oncotarget 2017 (epub). Go to original source... Go to PubMed...
    34. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4(9): 1046-1061. Go to original source... Go to PubMed...
    35. Planchard D, Loriot Y, André F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 2015; 26(10): 2073-2078. Go to original source... Go to PubMed...
    36. Steuer CE, Khuri FR, Ramalingam SS, et al. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer 2015; 121(8): E1-6. Go to original source... Go to PubMed...
    37. Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015; 16(8): 990-998. Go to original source... Go to PubMed...
    38. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl. 5): v1-v27. Go to original source... Go to PubMed...
    39. NCCN guidelines avaliable from www.nccn.org (https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf) .
    40. Sullivan I, Planchard D. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Frontiers in Medicine 2016; 3: 76. Go to original source...
    41. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327(20): 1434-1441. Go to original source... Go to PubMed...
    42. Schuette WH, Gröschel A, Sebastian M, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 2013; 14(3): 215-223. Go to original source... Go to PubMed...
    43. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2015; 10(1): 134-142. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.